Drugs / BGT-002
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06491576 | Mar 2023 → Mar 2024 | metabolic dysfunction-associated steatohepatitis | Burgeon Therapeutics Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGT-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06491576 ↗ |
| Route | Oral | “taking the study drug orally” NCT06491576 ↗ |